Laddar populära aktier...
Redeye retains its positive view of Vertiseit following a directed share issue.
Redeye provides its initial take on Scandion Oncology's Q1 2024 report.
Redeye provides a short research note following Scandinavian ChemoTech's anouncement of its first or...
Redeye comments on the new multi-year agreement that Dignitana has signed with Konica Minolta in Jap...
Redeye updates its view on Flexion Mobile following its Q1 2024 report.
We have talked to Lagercrantz's CEO, Jörgen Wigh, and VP Niche Products Divsion, Jonas Ahlberg, abou...
Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting...
DKK 650m order over eight years Renovation and expansion of electrical distribution network Strength...
Adjusted EBITDA of GBP 1.6m, +29% vs. ABGSCe We raise '24e-'26e EBITDA by 12-20% Share is trading at...
Redeye comments on the outcome of Alzecure’s rights issue, that secured some SEK39m before issue cos...
Lägre spelaraktivitet pressade kvartalet Mindark minskade omsättningen med 21,9 procent i det första...
Redeye comments on CLS’ strategy change with an increased focus on the neurosurgery segment.
CirChem (”CirChem” eller ”Bolaget”) har presenterat Bolagets Q1-rapport och fortsätter på den inslag...
Analysguiden sätter motiveraT värde till 33 kr som är baserad på en jämförande värdering.
Exel decided on the terms of its rights offering, which should enable strategy implementation after ...